Another NASH setback as CymaBay drops seladelparCymaBay Therapeutics has scrapped two mid-stage trials of seladelpar in non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), Share XAnother NASH setback as CymaBay drops seladelparhttps://pharmaphorum.com/news/another-nash-setback-as-cymabay-drops-seladelpar/
NHS orthopaedic hospital trials patient support appVeteran patients at a specialist NHS orthopaedic hospital can now benefit from an app that helps them feel Share XNHS orthopaedic hospital trials patient support apphttps://pharmaphorum.com/news/nhs-orthopaedic-hospital-trials-patient-support-app/
Blackstone and Ferring pump $570m into bladder cancer gene therapySwitzerland’s Ferring Pharmaceuticals has joined with US investor Blackstone Life Sciences to pump $570 million into a bladder Share XBlackstone and Ferring pump $570m into bladder cancer gene therapyhttps://pharmaphorum.com/news/blackstone-and-ferring-pump-570m-into-bladder-cancer-gene-therapy/
FDA rejects Adamis opioid overdose therapy Zimhi, hitting share priceShares in Adamis Pharmaceuticals have been poleaxed by an FDA decision to reject Zimhi, intended as a treatment Share XFDA rejects Adamis opioid overdose therapy Zimhi, hitting share pricehttps://pharmaphorum.com/news/fda-rejects-adamis-opioid-overdose-therapy-zimhi-hitting-share-price/
Conservatives shy away from drug price debate in election manifestoThe Conservative Party has pledged to encourage R&D in the UK’s life science industry should it win the Share XConservatives shy away from drug price debate in election manifestohttps://pharmaphorum.com/news/conservatives-shy-away-from-drug-price-debate-in-election-manifesto/
Few UK patients using digital products, despite doctors’ adviceFew patients in the UK are making use of digital products despite widespread backing from clinicians, according to Share XFew UK patients using digital products, despite doctors’ advicehttps://pharmaphorum.com/news/few-uk-patients-using-digital-products-despite-doctors-advice/
FDA cues up May verdict for Roche’s SMA challenger risdiplamThe FDA has started a priority review of Roche’s spinal muscular atrophy (SMA) candidate risdiplam, with a decision Share XFDA cues up May verdict for Roche’s SMA challenger risdiplamhttps://pharmaphorum.com/news/fda-cues-up-may-verdict-for-roches-sma-challenger-risdiplam/
Novartis to buy The Medicines Company for $9.7bnNovartis is to buy The Medicines Company and its cholesterol-lowering drug for $9.7 billion, confirming press speculation. The Share XNovartis to buy The Medicines Company for $9.7bnhttps://pharmaphorum.com/news/novartis-to-buy-the-medicines-company-for-9-7bn/
Takeda sets sights on first-line lung cancer market with new Alunbrig dataPfizer’s ALK inhibitor Xalkori is facing a further challenge from Takeda newcomer Alunbrig, which outperformed it in a Share XTakeda sets sights on first-line lung cancer market with new Alunbrig datahttps://pharmaphorum.com/news/takeda-sets-sights-on-first-line-lung-cancer-market-with-new-alunbrig-data/
